Literature DB >> 31317818

Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.

Carlos R Camara-Lemarroy1, Claudia Silva2, Jamie Greenfield3, Wei-Qiao Liu1, Luanne M Metz1, V Wee Yong1.   

Abstract

BACKGROUND: Recent evidence suggests a role for the gut-brain axis in the pathophysiology of multiple sclerosis (MS).
MATERIALS AND METHODS: We studied biomarkers of intestinal permeability in 126 people with MS (57 relapsing-remitting multiple sclerosis (RRMS) and 69 progressive MS) and in a group of healthy controls for comparison. Serum/plasma concentrations of zonulin (a regulator of enterocyte tight junctions), tight junction proteins (ZO-1 and occludin), intestinal fatty acid binding protein (IFABP)/ileal bile acid binding protein (IBABP), D-lactate, and lipopolysaccharide (LPS) binding protein were measured.
RESULTS: Zonulin concentrations were significantly higher when a concurrent magnetic resonance imaging (MRI) confirmed the presence of blood-brain barrier (BBB) disruption (Gad+ RRMS) and were correlated with tight junction proteins. IBABP and D-lactate were elevated in people with RRMS compared to controls, but did not discriminate between Gad+ and Gad- subgroups. Baseline zonulin concentrations were associated with 1-year disease progression in progressive MS.
CONCLUSIONS: People with MS have altered biomarkers of intestinal barrier integrity. Zonulin concentrations are associated with 1-year disease progression in progressive MS and closely mirror BBB breakdown in RRMS. Zonulin may mediate breakdown of both the intestinal barrier and the BBB in gut dysbiosis through the regulation of tight junctions. This could explain how the gut-brain axis modulates neuroinflammation in MS.

Entities:  

Keywords:  Multiple sclerosis; blood–brain barrier; intestinal barrier; zonulin

Year:  2019        PMID: 31317818     DOI: 10.1177/1352458519863133

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  18 in total

1.  Zonulin and blood-brain barrier permeability are dissociated in humans.

Authors:  Charlotte M Stuart; Aravinthan Varatharaj; Martin E Winberg; Pascale Galea; Henrik B W Larsson; Stig P Cramer; Alessio Fasano; Zaynah Maherally; Geoffrey J Pilkington; Åsa V Keita; Ian Galea
Journal:  Clin Transl Med       Date:  2022-07

2.  The Zonulin-transgenic mouse displays behavioral alterations ameliorated via depletion of the gut microbiota.

Authors:  Alba Miranda-Ribera; Gloria Serena; Jundi Liu; Alessio Fasano; Marcy A Kingsbury; Maria R Fiorentino
Journal:  Tissue Barriers       Date:  2021-11-14

Review 3.  Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?

Authors:  Cezmi A Akdis
Journal:  Nat Rev Immunol       Date:  2021-04-12       Impact factor: 53.106

Review 4.  Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity.

Authors:  Yusuke Kinashi; Koji Hase
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 5.  Targeting the gut to treat multiple sclerosis.

Authors:  Laura Ghezzi; Claudia Cantoni; Gabriela V Pinget; Yanjiao Zhou; Laura Piccio
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

Review 6.  Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment.

Authors:  Eduardo Duarte-Silva; Sven G Meuth; Christina Alves Peixoto
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 4.677

Review 7.  All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases.

Authors:  Alessio Fasano
Journal:  F1000Res       Date:  2020-01-31

8.  Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis.

Authors:  Marina Saresella; Ivana Marventano; Monica Barone; Francesca La Rosa; Federica Piancone; Laura Mendozzi; Alessia d'Arma; Valentina Rossi; Luigi Pugnetti; Gabriella Roda; Eleonora Casagni; Michele Dei Cas; Rita Paroni; Patrizia Brigidi; Silvia Turroni; Mario Clerici
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

9.  Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development.

Authors:  Siddhartha S Ghosh; Jing Wang; Paul J Yannie; Shobha Ghosh
Journal:  J Endocr Soc       Date:  2020-02-20

10.  Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease.

Authors:  Diana E Matei; Madhvi Menon; Dagmar G Alber; Andrew M Smith; Bahman Nedjat-Shokouhi; Alessio Fasano; Laura Magill; Amanda Duhlin; Samuel Bitoun; Aude Gleizes; Salima Hacein-Bey-Abina; Jessica J Manson; Elizabeth C Rosser; Nigel Klein; Paul A Blair; Claudia Mauri
Journal:  Med (N Y)       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.